HCW Biologics leads Cardio Diagnostics on 9 of 14 measures

HCW Biologics beat Cardio Diagnostics on 9 of 14 measures in a Ticker Report trade-press article published Oct. 11, 2026, covering profitability, valuation, analyst ratings, ownership and risk.

Ticker Report's Oct. 11 article compared two Nasdaq-listed small-cap healthcare companies with limited revenue, listing HCW Biologics at $50,000 in gross revenue versus $10,000 for Cardio Diagnostics, without specifying the reporting period.

The comparison leaned on MarketBeat-supplied analyst data. HCW Biologics had one sell rating and one buy rating, for a rating score of 2.00, while Cardio Diagnostics had one sell rating and a score of 1.00, according to the article. HCW Biologics' consensus target price was listed at $30.00, implying potential upside of 1,775.00% from the referenced share price.

Ownership was mixed. Institutions held 3.0% of HCW Biologics shares, compared with 8.1% of Cardio Diagnostics shares. Insider ownership was almost the same, at 9.1% for HCW Biologics and 9.0% for Cardio Diagnostics.

Both stocks carried high market sensitivity. HCW Biologics had a beta of 2.41, a measure of volatility relative to the S&P 500, while Cardio Diagnostics had a beta of 2.29, according to the article.

The financial comparison showed both companies losing money. HCW Biologics had net income of negative $7.96 million and earnings per share of negative $27.60, while Cardio Diagnostics had net income of negative $6.50 million and earnings per share of negative $2.92. Because both earnings figures were negative, price-to-earnings comparisons are less informative than for profitable companies.

HCW Biologics, based in Miramar, Florida, is a clinical-stage biopharmaceutical company developing immunotherapies. Cardio Diagnostics, based in Chicago, develops epigenetics-based clinical tests for cardiovascular disease.